Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OvaRex as Adjuvant to Chemotherapy in Advanced Ovarian Cancer
NCT00086632Phase 2Terminated
- Sponsor
- Unither Pharmaceuticals
- Start
- Jul 2004
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of oregovomab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Unither Pharmaceuticals. Started Jul 2004; status: terminated.
02
Drugs
oregovomab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00086632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00086632.